Published in BMJ on October 23, 1999
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst (1997) 1.88
Endogenous complement C3 synthesis in immune complex nephritis. Lancet (1993) 1.57
Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem (1984) 1.54
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Free proximal trisomy 21 without the Down syndrome. Clin Genet (1987) 1.19
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Cancer incidence in the industrial corridor: an update. J La State Med Soc (1998) 1.17
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc (1997) 1.14
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
Renal disease and use of topical non-steroidal anti-inflammatory drugs. BMJ (1994) 1.10
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
Outcome of transplantation of non-heart-beating donor kidneys. Lancet (1995) 1.09
Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res (1996) 1.05
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest (1990) 1.03
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
The adducted thumbs syndrome. An autosomal recessive disease with arthrogryposis, dysmyelination, craniostenosis, and cleft palate. Clin Genet (1971) 0.97
Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos (1980) 0.96
Hypermethylation of human DNA sequences in embryonal carcinoma cells and somatic tissues but not in sperm. Nucleic Acids Res (1987) 0.96
Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab Dispos (1995) 0.91
Renal failure in a patient with chronic myelomonocytic leukaemia. Nephrol Dial Transplant (1997) 0.91
Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol (1998) 0.91
High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol (1985) 0.90
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res (1991) 0.89
Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol (1985) 0.88
Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res (1989) 0.88
Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chem Biol Interact (1998) 0.88
NSAIDS in the postoperative period. Many factors threaten renal function. BMJ (1993) 0.87
Predictive value of preclinical toxicology studies for platinum anticancer drugs. Clin Cancer Res (1999) 0.87
Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis (2002) 0.87
Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett (1987) 0.86
Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol (2000) 0.86
Modulation of cis-diamminedichloroplatinum (II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. Eur J Cancer (1997) 0.84
Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion. Mol Pharmacol (1986) 0.83
Inhibitors of intracellular pH regulation induce cisplatin resistance in EMT6 mouse mammary tumor cells. Oncol Res (1995) 0.82
Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut (2012) 0.82
Is there a 'cancer corridor' in Louisiana? J La State Med Soc (1996) 0.81
Ring chromosome 12. Am J Med Genet (1988) 0.80
Racial variation in dosage requirements of tacrolimus. Lancet (1996) 0.80
The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun (1990) 0.80
Cancer of the colon and rectum in Louisiana. J La State Med Soc (1999) 0.80
Poorer graft survival in ethnic minorities: results from a multi-centre UK study of kidney transplant outcomes. Clin Nephrol (2011) 0.80
Nocturnal body temperature regulation in man: a rationale for sweating in sleep. J Appl Physiol (1966) 0.79
Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol (1997) 0.79
A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Anal Biochem (1984) 0.78
Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol (1982) 0.78
Kidney donation after paracetamol overdose. BMJ (1993) 0.78
Rapid determination of C-reactive protein levels: semiquantitative versus quantitative. J Pediatr (1987) 0.78
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer (1990) 0.78
Highlights of cancer incidence in Louisiana, 1988-1992. J La State Med Soc (1997) 0.78
Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res (1992) 0.78
A regulatory view of the Medicines Act in the United Kingdom. J Clin Pharmacol (1984) 0.78
Pharmacokinetic study of intraperitoneal streptozotocin. Clin Invest Med (1992) 0.78
Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link? Drug Saf (2001) 0.77
Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. Clin Cancer Res (1996) 0.77
Cellular pharmacologic strategies for overcoming drug resistance: potential applications to regional therapy. Eur J Surg Suppl (1991) 0.77
Renal transplantation in a patient with loin pain hematuria syndrome. Clin Nephrol (2006) 0.77
Breast cancer: incidence, mortality, and early detection in Louisiana, 1988-1997. J La State Med Soc (2001) 0.77
Drug accumulation and DNA platination in cells exposed to aquated cisplatin species. Cancer Lett (1994) 0.77
Renal transplantation in Wiskott-Aldrich syndrome. Transplantation (1993) 0.77
Disorders of iron metabolism. N Engl J Med (2000) 0.77
Increase in the ATP signal after treatment with cisplatin in two different cell lines studied by 31P NMR spectroscopy. Biochem Biophys Res Commun (1992) 0.76
Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Implications for renal transplantation. Nephrol Dial Transplant (1999) 0.76
Preclinical and clinical experience with cisplatin resistance. Hematol Oncol Clin North Am (1995) 0.76
Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant (1995) 0.76
Antiphospholipid syndrome and systemic lupus erythematosus. Lancet (1993) 0.76
Asymptomatic haematuria. Nephrological screening is important. BMJ (2000) 0.75
Oversensitive dipsticks? A minimalist take on urinalysis for microscopic haematuria. Int J Clin Pract (2008) 0.75
Diarrhoea as a side effect of digoxin. BMJ (1990) 0.75
Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. Int J Clin Pract (2010) 0.75
Percutaneous endoscopic gastrostomy feeding. BMJ (1992) 0.75
Considerations for toxicology studies of respiratory drug products. Regul Toxicol Pharmacol (1997) 0.75
The care of patients undergoing hemodialysis. N Engl J Med (1999) 0.75
Heart failure. Lancet (1998) 0.75
Centoxin: the full story of its withdrawal. Br J Hosp Med (1993) 0.75
Cervical myxofibrosarcoma in a renal allograft recipient treated with murine anti-CD3 monoclonal antibody therapy. Nephrol Dial Transplant (1998) 0.75
Successful pregnancy in cystinosis. JAMA (1994) 0.75
Palliative care for patients with terminal renal failure. Lancet (1995) 0.75
Anti-glomerular basement membrane antibody-mediated nephritis: when not to treat. Nephrol Dial Transplant (1999) 0.75
Risk of pneumonia after hospital treatment for pneumonia. Lancet (1992) 0.75
Outcome of renal transplantation in Wiskott-Aldrich syndrome. Nephrol Dial Transplant (1998) 0.75
Qualitative analysis of trimethylsilylated daunosamine and N-alkylated analogs by gas chromatography--mass spectrometry. Anal Biochem (1982) 0.75
Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur J Cancer (1990) 0.75
Disposition and metabolism of adriamycin octanoylhydrazone (NSC 233853) in mice and rabbits. Drug Metab Dispos (1981) 0.75
The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. Biochim Biophys Acta (1995) 0.75
Rhesus immunization after renal transplantation. Transplantation (1996) 0.75
Cellular resistance to platinating agents in ovarian carcinoma. Prog Clin Biol Res (1986) 0.75
Louisiana Tumor Registry: new developments and activities. J La State Med Soc (1999) 0.75
Aviator's cancer. Lancet (1968) 0.75
Disposition and metabolism of N,N-dimethyldaunorubicin and N,N-dimethyladriamycin in rabbits and mice. Drug Metab Dispos (1981) 0.75
Growth inhibition by thymidine of leukemic HL-60 and normal human myeloid progenitor cells. Cancer Res (1981) 0.75
Systemic and topical actions of leucocytic extracts on minute vessels of the bat wing. Bibl Anat (1967) 0.75
Intravascular haemolysis and interstitial nephritis in association with ciprofloxacin. Nephron (1999) 0.75
The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol (1987) 0.75
Purification and characterization of aclacinomycin A and its metabolites from human urine. Drug Metab Dispos (1983) 0.75
Advanced stage at diagnosis: an explanation for higher than expected cancer death rates in Louisiana? J La State Med Soc (1994) 0.75
The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol (1997) 0.75
Superoxide radical reactions with anthracycline antibiotics. Biochem Pharmacol (1985) 0.75
Reversed-phase high-performance liquid chromatography analysis of 6-thioguanine applicable to pharmacologic studies in humans. J Chromatogr (1982) 0.75
Post-transplantation lymphoproliferative disorder: an unusual presentation in a patient receiving tacrolimus. Nephrol Dial Transplant (2000) 0.75